全球产业分工重构之际，中国医疗器械正加速突破技术壁垒，向全球产业链中高端迈进。在这一浪潮 中，医疗健康领域龙头鱼跃医疗的深入布局，可称为产业链协同出海的典型样本。 近日，鱼跃医疗(002223.SZ)发布公告称，控股子公司江苏鱼跃凯立特生物科技有限公司（以下简称"鱼 跃凯立特"）收到了TüV SüD Product Service GmbH的通知，公司申请的持续葡萄糖监测系统获得符合欧 盟《医疗器械第2017/745号法规》（Medical Devices Regulation（EU）2017/745，简称"MDR"）要求的 IIb类医疗器械CE认证证书。 这意味着鱼跃医疗的持续葡萄糖监测系统（CGM）已经获得国际认可，不仅有望推动其持续血糖监测 技术和成果走向世界舞台，更标志着中国医疗器械的发展已经从创新叙事进入价值兑现。 血糖监测技术达到头部水平 资料显示，作为医疗健康产业的先行者和探索者，近年来鱼跃医疗重点聚焦呼吸治疗、血糖管理及 POCT、家用健康检测等业务板块，以强大的研发实力和创新能力为支撑，致力于为全球患者和医疗机 构提供高质量的医疗产品和服务。 其中，血糖管理及POCT板块自2022年以来，持 ...

Core Viewpoint - Yuyue Medical is steadily advancing towards a new cycle of high-quality development under the clear guidance of its three major strategies: globalization, digitalization, and wearability [2] Financial Performance - In the first three quarters of this year, the company achieved operating revenue of 6.545 billion yuan, a year-on-year increase of 8.58% [2] - The net profit attributable to shareholders reached 1.466 billion yuan, with operating cash flow net amounting to 1.504 billion yuan, reflecting a year-on-year growth of 8.77% [2] - The company plans to implement its first-ever third-quarter dividend since its listing, distributing 2 yuan per 10 shares, bringing the total dividends to 4.959 billion yuan [2] R&D and Product Innovation - Yuyue Medical has significantly increased its R&D investment, reaching 445 million yuan in the first three quarters, a year-on-year increase of 9.76% [3] - The gross profit margin has risen to 50.35%, driven by rapid product iteration and an increase in high-end product offerings [3] - The company has launched several new products across various business segments, including CGM devices and respiratory treatment products, enhancing its competitive edge [3][4] Market Performance and Strategy - The CGM product line has seen a rapid increase in sales and market share, with a 165% sales growth during the 618 shopping festival on JD.com [4] - The fifth-generation CGM product has achieved global leading technical indicators, with a MARD value of 8.58%, catering to both clinical and home use scenarios [4] - Yuyue Medical is leveraging AI technology to enhance its product offerings and health management services, positioning itself as a leader in the home medical device sector [5][6] Global Expansion - The company has experienced a 26.63% year-on-year growth in overseas revenue, with significant breakthroughs in multiple international markets [6][7] - Yuyue Medical has established subsidiaries in countries like Germany, Thailand, and the USA, focusing on localized product development and market strategies [7] - The company aims to set up more subsidiaries in Europe, South America, and the Middle East, with a vision to become one of the top three players in the global OOH medical device market [7][8] Industry Outlook - The Chinese medical device industry is poised for growth due to favorable policies, increasing demand from an aging population, and advancements in AI and new materials [8] - Yuyue Medical is expected to amplify its leading position in the industry as it capitalizes on these opportunities and continues to enhance its global presence [8]